Fig. 1: Significant perturbation in the serum metabolome of lung adenocarcinoma compared with healthy controls and benign nodules. | Nature Communications

Fig. 1: Significant perturbation in the serum metabolome of lung adenocarcinoma compared with healthy controls and benign nodules.

From: Metabolomic differentiation of benign vs malignant pulmonary nodules with high specificity via high-resolution mass spectrometry analysis of patient sera

Fig. 1: Significant perturbation in the serum metabolome of lung adenocarcinoma compared with healthy controls and benign nodules.

a The study population of serum global metabolomic analysis by ultra-performance liquid chromatography-high resolution mass spectrometry (UPLC-HRMS) in the discovery cohort. b The partial least squares discrimination analysis (PLS-DA) of the global metabolomes of 480 serum samples in the discovery cohort including heathy controls (HC, n = 174), benign nodules (BN, n = 170), and stage I lung adenocarcinoma (LA, n = 136). +ESI, positive electrospray ionization mode; −ESI, negative electrospray ionization mode. c–e Significant differentially abundant metabolites between two given groups (Two-sided Wilcoxon rank tests with the p value adjusted by false discovery rate, FDR < 0.05) are shown in red (fold change > 1.2) and blue (fold change < 0.83) in the volcano plot. f A hierarchical clustering heat map showing significantly differential abundance of annotated metabolites between LA and BN. Source data are provided as a Source Data file.

Back to article page